Tracon Pharmaceuticals, Inc.
DelistedCIK 1394319fmd_08JJYZ5Z71MGJSSH9XR1WBA0WJManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2013 to Jun 30, 2024, 43 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 3 | 9 | 3 | 0 | 0 | 0 | 0 | 12 |
| Net interest income | (1) | (1) | – | – | – | – | – | – | – | – |
| Research and development | 8 | 26 | 22 | 19 | 30 | 15 | 8 | 11 | 14 | 12 |
| Total operating expenses | 10 | 31 | 29 | 27 | 38 | 22 | 16 | 29 | 28 | 21 |
| Operating income | (6) | (23) | (26) | (18) | (35) | (22) | (16) | (28) | (28) | (9) |
| Other non-operating income (expense) | (1) | (1) | (1) | (1) | (0) | (0) | (1) | (0) | (1) | 6 |
| Income tax expense | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (7) | (24) | (27) | (19) | (35) | (23) | (17) | (29) | (29) | (4) |
| Net income to common shareholders | (7) | (24) | (27) | (19) | – | – | – | – | – | – |